Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with ...

43rd Annual J.P. Morgan Healthcare Conference – Company Presentation Date: Wednesday, January 15, 2025 Time: 3:45 p.m. - 4:25 p.m. PT Location: The Westin St. Francis Hotel, San Francisco, CA ...

Additional clinical results from Phase 1/2 study of MRT-2359 in MYC-driven solid tumors, including biomarker and activity data, anticipated in Q1 2025 MRT-8102, a NEK7-directed MGD targeting diseases ...

Novel Self-Assembly DisAssembly Pre-targeted Radioimmunotherapy (“SADA PRIT”) platform designed to improve upon traditional radioimmunotherapy by delivering high therapeutic dose while minimizing ...

More than 8,000 healthcare professionals will descend on San Francisco starting Monday for the 43rd annual J.P. Morgan ...

ElevateBio is a technology-driven company built to power transformative genetic medicines today and for many decades to come. The Company commercializes its enabling technologies, manufacturing ...

Lyell is focused on advancing next-generation CAR T cell therapies with the potential to deliver higher response rates and longer duration of responses for patients with hematologic malignancies and ...

STAT reporters discuss why a looming patent cliff could lead to more pharmaceutical deal-making and a new obesity startup.

J.P. Morgan releases its quarterly look-ahead days before the entire biopharma industry descends on San Francisco for the ...

Ginkgo Bioworks , which is building the leading platform for cell programming and biosecurity, today announced that Co-Founder and CEO, Jason Kelly, is scheduled to present at the 43rd Annual J.P.